Axicabtagene Ciloleucel & Brexucabtagene Autoleucel

Yescarta & Tecartus

Potential risk of T-cell malignancy associated with the use of chimeric antigen receptor (CAR) T cell Immunotherapies.• Secondary malignancies of T-cell origin, including chimeric antigen receptor (CAR)- positive malignancies, have been reported within weeks and up to several years following treatment of haematological malignancies with a BCMA- or CD19-directed CAR T-cell therapy. • Patients should be monitored life-long for secondary malignancies.